WO2016098874A1 - 内服用組成物 - Google Patents

内服用組成物 Download PDF

Info

Publication number
WO2016098874A1
WO2016098874A1 PCT/JP2015/085450 JP2015085450W WO2016098874A1 WO 2016098874 A1 WO2016098874 A1 WO 2016098874A1 JP 2015085450 W JP2015085450 W JP 2015085450W WO 2016098874 A1 WO2016098874 A1 WO 2016098874A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
fucoxanthin
lactoferrin
composition
fat
Prior art date
Application number
PCT/JP2015/085450
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
森下　聡
佳菜恵 中村
大原　勝義
桂子 関
知二 小野
健 上北
Original Assignee
ライオン株式会社
株式会社カネカ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社, 株式会社カネカ filed Critical ライオン株式会社
Priority to KR1020177015167A priority Critical patent/KR20170095843A/ko
Priority to CN201580069149.8A priority patent/CN107106633A/zh
Publication of WO2016098874A1 publication Critical patent/WO2016098874A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a composition for internal use.
  • Non-patent Document 1 Various substances are known as food materials that can reduce visceral fat. It has been reported that tea catechin is effective for dietary obesity when taken for a long time (Non-patent Document 1). In addition, it has been reported that polyphenol-enriched oolong tea beverage has an effect of suppressing an increase in serum triglyceride after meal (Non-patent Document 2).
  • lactoferrin is a trace protein present in milk, its hydrolyzate has an antibacterial action (Non-patent Document 3), and immunity is obtained in healthy individuals who have orally administered capsules containing bovine lactoferrin. It has been reported that the activation effect is exhibited (Non-patent Document 4). It has also been reported that the intestinal solvent of lactoferrin suppresses fat accumulation and reduces visceral fat by decomposing the accumulated fat (Non-Patent Documents 5, 6 and 7).
  • Fucoxanthin is a type of carotenoid contained in seaweeds such as brown algae and organisms such as microalgae at high concentrations.
  • Non-Patent Document 8 describes that a component containing fucoxanthin can reduce body weight and fat content in liver and liver in obese women who are not diabetic.
  • Non-Patent Document 9 and Patent Document 1 describe the action mechanism of fucoxanthin. That is, it is described that UCP1 (mitochondrial uncoupling protein), which is a fat burning protein, is not normally expressed in white adipocytes, but its expression is increased by fucoxanthin. On the other hand, the expression of brown adipocytes that originally highly express UCP1 is further increased by fucoxanthin.
  • UCP1 mitochondrial uncoupling protein
  • lactoferrin is a trace amount of protein, and it cannot be said that a sufficient amount is supplied as a practically usable raw material. Therefore, it has been desired to develop a means that can exert the fat reduction effect that is the original effect of lactoferrin without being influenced by the amount of lactoferrin used.
  • fucoxanthin is only reported to have a fat reduction effect alone, and can be combined with other components, and at least in combination with other components, can increase the fat reduction effect. It was not known.
  • An object of the present invention is to find a composition for internal use that can exhibit a good fat reduction effect.
  • the present invention provides the following [1] to [13].
  • a composition for internal use comprising component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • component (a) lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • a body fat reducing agent comprising as an active ingredient component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • Weight loss promoting agent comprising as an active ingredient component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • a blood neutral fat reducing agent comprising as an active ingredient component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • a blood free fatty acid reducing agent comprising as an active ingredient component (a): lactoferrin and component (b): fucoxanthin.
  • the agent according to any one of [3] to [6], wherein the ratio of the content of component (b) to the content of component (a) is 0.0001 or more and less than 0.3.
  • Agent. [10] Component (a): lactoferrin and component (b): fucoxanthin and / or its metabolites are administered to a subject in need thereof to prevent, ameliorate or treat hypertension, hyperglycemia or dyslipidemia Method.
  • composition comprising fucoxanthin and / or its metabolite, a body fat reducing agent, a weight loss promoting agent, a blood neutral fat reducing agent, and a blood release
  • Non-medical use as one or more selected from fatty acid reducing agents.
  • Use of a composition comprising component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof for the prevention, amelioration or treatment of hypertension, hyperglycemia or dyslipidemia.
  • an internal use composition capable of exhibiting at least one selected from a body fat reducing effect, a neutral fat reducing effect, a weight reducing effect and a free fatty acid reducing effect.
  • composition for internal use of the present invention comprises component (a): lactoferrin and component (b): fucoxanthin and / or a metabolite thereof.
  • Component (a) is lactoferrin.
  • lactoferrin The origin and production method of lactoferrin is not particularly limited, and examples thereof include lactoferrin derived from mammalian milk, lactoferrin derived from plants, and artificially produced lactoferrin. Lactoferrin may be a commercially available product.
  • Mammals include humans, horses, cows, sheep and goats.
  • conventional methods for example, ion treatment
  • mammalian milk eg, colostrum, transitional milk, normal milk, end milk
  • processed milk products such as skim milk and whey.
  • a method for separating lactoferrin by exchange chromatography is exemplified. Examples of plants include tomato, rice and tobacco.
  • Lactoferrin may contain metal ions. That is, component (a) may be either apolactoferrin (lactoferrin containing no metal ions) or hololactoferrin (lactoferrin containing metal ions), or both.
  • the metal ion which lactoferrin may contain is not specifically limited, An iron ion and a copper ion are illustrated and an iron ion is preferable.
  • lactoferrin contains a metal ion, the amount is not limited and may be one or two or more.
  • Examples of hololactoferrin include iron lactoferrin (lactoferrin having 3 or more iron ions in one molecule of lactoferrin).
  • lactoferrin examples include biological techniques such as genetic recombination techniques and chemical techniques such as chemical synthesis.
  • Component (a) may be a single lactoferrin or a combination of two or more lactoferrin.
  • Lactoferrin is preferably lactoferrin derived from bovine milk (bovine lactoferrin) for reasons such as availability and low cost.
  • a lower limit is 0.1 mass% or more, More preferably, it is 0.5 mass% or more, More preferably Is 1% by mass or more.
  • the upper limit of the content of component (a) is generally 70% by mass or less, preferably 50% by mass or less, and more preferably 40% by mass or less.
  • Component (b) is fucoxanthin and / or its metabolite.
  • fucoxanthin metabolites include fucoxanthinol and amarocyanoxanthin.
  • generation method of a fucoxanthin and its metabolite Any of a natural product origin, an artificial manufactured product, and a commercial item may be sufficient.
  • Examples of natural products include algae.
  • Examples of the algae include brown algae such as kombu, akamoku, hijiki, mozuku, and seaweed, green algae such as aosa and aonori, red algae such as asakusanori and agus, and microalgae.
  • brown algae is preferable.
  • the method for obtaining fucoxanthin and / or its metabolite from a natural product is not particularly limited, and examples thereof include a method of extracting from a natural product using an extraction solvent and then purifying as necessary.
  • the extraction solvent is not particularly limited as long as fucoxanthin and / or a metabolite thereof can be extracted from a natural product, such as water; alcohol (methanol, ethanol, propanol, butanol, etc.); ketone (acetone, methyl ethyl ketone, etc.); acetonitrile; Ether (diethyl ether, diisopropyl ether, diethylene glycol diethyl ether, tetrahydrofuran, etc.); halogenated hydrocarbon (dichloromethane, chloroform, etc.); ester (ethyl acetate, etc.); aliphatic hydrocarbon (pentane, hexane, cyclohexane, etc.); aromatic carbonization Hydrogen (benzene, toluene, xylene, etc.); and a mixture of two or more of these.
  • a natural product such as water; alcohol (methanol, ethanol, propanol, butan
  • the extraction solvent is preferably a solvent containing one or more selected from alcohols, ethers, aliphatic hydrocarbons and water, more preferably a mixed solvent of ethanol, hexane and saline, and diethyl ether.
  • the extraction may be performed once or twice or more, and is preferably performed twice.
  • the first extraction solvent is preferably a mixed solvent of ethanol, hexane and saline, and the second extraction solvent is preferably diethyl ether.
  • Purification may be performed by chromatography and / or recrystallization.
  • the developing solvent in chromatography include a mixed solvent of hexane and acetone.
  • the recrystallization method include a method in which a sample is dissolved in a solvent such as acetone and allowed to stand, and then the solvent is distilled off by means of reduced pressure, heating or the like and then cooled.
  • artificial manufacturing methods include biological techniques such as genetic recombination techniques and chemical techniques such as chemical synthesis.
  • the purity of fucoxanthin and its metabolites is not particularly limited.
  • the purity need not be 100%, and may be, for example, 30% or less, 70% or less, and 90% or less. Purity may be adjusted by purification.
  • the purification method is not particularly limited, and examples thereof include extraction with a solvent, column chromatography, and recrystallization.
  • fucoxanthin and its metabolites there are no particular limitations on the form of fucoxanthin and its metabolites, and examples include oily forms, crystalline forms, and amorphous forms.
  • Component (b) may be a single species selected from the above group, or a combination or mixture of two or more fucoxanthins.
  • the content of the component (b) in the composition for internal use of the present invention is not particularly limited, but the lower limit is preferably 0.0001% by mass or more, more preferably 0.0005% by mass or more, Even more preferably, it is 0.001 mass% or more.
  • the upper limit of the content of component (b) is generally 10% by mass or less, preferably 5% by mass or less, and more preferably 3% by mass or less.
  • the composition containing an ingredient (b) may be added to the composition for internal use.
  • the composition include the above-mentioned natural products, extracts and purified products thereof.
  • One type or two or more types of compositions containing component (b) may be added.
  • the content of the component (b) in the composition for internal use means not the content of the composition but the content of the component (b) contained in the composition.
  • the application amount of the composition for internal use of the present invention is not particularly limited. Conditions of the animal to be administered (eg, type, weight, age, severity of symptoms, etc.), desired efficacy can be obtained, and cost is reduced. It can be set as appropriate according to reasons such as suppression and safety.
  • the application amount of component (a) is usually 10 mg to 2000 mg / day, preferably 50 mg to 900 mg / day, more preferably 100 mg to 600 mg / day.
  • the application amount of component (b) is usually 0.01 mg to 10 mg / day, preferably 0.1 mg to 5 mg / day, and more preferably 0.3 mg to 3 mg / day.
  • the ratio of the content of component (b) to the content of component (a) (mass ratio in terms of solid content: (b) / (a)), body fat reduction action, blood neutral fat reduction It can be appropriately set depending on the reason such as the action, the weight loss promoting action, the blood free fatty acid reducing action, etc., and the cost can be suppressed.
  • the lower limit of (b) / (a) is preferably 0.0001 or more, more preferably 0.0005 or more, and still more preferably 0.001 or more.
  • the upper limit value is preferably less than 0.3, and more preferably 0.1 or less.
  • (B) / (a) is preferably 0.0001 or more and less than 0.3, more preferably 0.0005 or more and less than 0.3, and still more preferably 0.001 or more and 0.1 or less.
  • the subject of application of the composition for internal use of the present invention is usually a mammal.
  • Mammals include humans, domestic animals (eg, horses, cows, sheep, pigs, goats, donkeys), pets (eg, dogs, cats), laboratory animals (eg, guinea pigs, mice, hamsters, rats, rabbits), etc. Is exemplified. Of these, humans are preferred. Pet animals are also preferred because, for example, metabolic disorders have recently become a problem.
  • the composition for internal use of the present invention can reduce fat.
  • Fat reduction means that when the application subject ingests the composition for internal use, the fat in the application subject decreases, and when the application subject ingests the composition for internal use at the same time as other foods, It is exemplified that fat can be prevented from increasing.
  • the composition for internal use of the present invention can reduce body fat.
  • the body fat may be visceral fat, subcutaneous fat, or both, but is preferably visceral fat. Reducing body fat means that the same amount after application is reduced as compared to the amount of body fat in the application target before application of the composition for internal use of the present invention.
  • body fat mass index Reduction in body fat can be confirmed by a change in the body fat mass index before and after application of the composition for internal use of the present invention.
  • the body fat mass index include numerical values such as body fat area, abdominal circumference, body fat percentage, and subcutaneous fat mass.
  • the area of body fat and the amount of subcutaneous fat may be calculated from an image (CT image) obtained by computed tomography of the abdominal peripheral section.
  • the waist circumference may be measured for the application target.
  • the body fat percentage may be estimated from the measurement result by the bioelectrical impedance method.
  • the body fat may be quantified using a commercially available kit.
  • the composition for internal use of the present invention can reduce neutral fat.
  • the neutral fat is an ester of glycerol and a fatty acid such as a saturated fatty acid or an unsaturated fatty acid, and examples thereof include triglyceride, diglyceride, and monoglyceride. Reducing neutral fat means that the same amount after application is reduced as compared to the amount of neutral fat in the whole body or a part of the application target before application of the composition for internal use of the present invention. To do.
  • part when the amount of neutral fat in a part of the application is reduced, and the circulatory organ or part thereof (eg, heart, blood vessel), blood or its components (eg, serum, plasma) ), Body fat or part thereof, liver or part thereof.
  • the circulatory organ or part thereof eg, heart, blood vessel
  • blood or its components eg, serum, plasma
  • the reduction of neutral fat can be confirmed by measuring the amount of neutral fat before and after application of the composition for internal use of the present invention.
  • neutral fat is decomposed into glycerin and fatty acid by enzyme (eg, lipoprotein kinase) or alkali (eg, methanolic KOH), and neutral fat is indirectly produced from the produced glycerin.
  • enzyme eg, lipoprotein kinase
  • alkali eg, methanolic KOH
  • glycerol is converted to glycerol-3-phosphate using an enzyme or the like, and a pigment is quantitatively produced from glycerol-3-phosphate
  • a method of quantifying neutral fat by measuring the pigment concentration a method of quantifying neutral fat by decomposing neutral fat into glycerin and fatty acid and quantifying the generated free fatty acid.
  • Neutral fat may be quantified using a commercially available kit.
  • composition for internal use of the present invention can promote weight loss. Promoting a decrease in body weight can be confirmed by measuring the body weight before and after application of the composition for internal use of the present invention.
  • the composition for internal use of the present invention can reduce free fatty acids.
  • a free fatty acid means what is not ester among the fatty acids which exist in the living body. Reducing free fatty acid means that the same amount after application is reduced as compared to the amount of free fatty acid in the whole body or a part of the application target before application of the composition for internal use of the present invention.
  • part when the amount of free fatty acid in a part of the application target is reduced, and it may be the same as the definition of “part” described for the neutral fat.
  • the reduction of free fatty acid can be confirmed by measuring the amount of free fatty acid before and after application of the composition for internal use of the present invention.
  • the free fatty acid may be quantified according to a conventional method, and a commercially available kit may be used.
  • the composition for internal use of the present invention can reduce body fat. Therefore, the purpose of ingesting the composition for internal use of the present invention is to reduce accumulated body fat, prevent body fat accumulation, alleviate body fat increase, prevent obesity, improve obesity, metabolic abnormality syndrome (metabolic syndrome), etc. Examples are prevention and / or alleviation of diseases that can be caused by increased body fat.
  • the composition for internal use of the present invention can reduce neutral fat. Therefore, the purpose of taking the composition for internal use of the present invention is to reduce accumulated neutral fat, prevent neutral fat accumulation, alleviate increase in neutral fat, prevent obesity, improve obesity, metabolic disorder syndrome (metabolic) Syndrome), dyslipidemia, diabetes, cardiovascular disease (eg, arteriosclerosis, angina), liver disease (eg, fatty liver, cirrhosis), etc. to prevent and / or alleviate by reducing triglycerides Illustrated.
  • composition for internal use of the present invention there is no particular limitation on the health condition of the application target of the composition for internal use of the present invention. Moreover, fats such as body fat and neutral fat may actually be accumulated in the body, or may not be accumulated.
  • the composition for internal use of the present invention may be taken by the application subject itself for the purpose exemplified above or may be ingested by the subject around the application subject for the purpose exemplified above. Good.
  • the administration route of the composition for internal use of the present invention is not particularly limited as long as it is oral administration, that is, administration taken from the mouth.
  • the administration method of the composition for internal use of the present invention can be appropriately determined depending on conditions such as the concentration of active ingredient, dosage form, application target (eg, age, weight, sex, health condition, degree of fat accumulation).
  • Examples of the administration method when the dosage form is a tablet include a method of taking it together with water.
  • the dosing interval can be determined as appropriate, and may be before meal, after meal, at the same time as eating or between meals. It is preferably administered before the start of exercise (sports). Thereby, fat burning by exercise can be further promoted.
  • composition for internal use of the present invention may contain any component.
  • Optional ingredients include excipients, diluents, buffers, flavoring agents, coloring agents, flavoring agents, sweeteners, binders, surfactants, thickeners, lubricants, suspending agents, preservatives And pharmacologically acceptable carriers such as antioxidants, abrasives, wetting agents, binders, pH adjusters, brighteners, medicinal components, solvents, and other auxiliary components commonly used in oral compositions.
  • the One arbitrary component may be sufficient as it, and 2 or more types may be sufficient as it.
  • Arbitrary components can be appropriately selected depending on the dosage form.
  • Examples of the dosage form of the composition for internal use of the present invention include solid forms such as small tablets, tablets, powders, granules, sachets, microcapsules, capsules, gummi, etc .; aqueous solutions, suspensions, syrups, emulsions, etc.
  • Liquid mode Semi-liquid, cream, paste, gel, etc .; Solid mode such as small tablet, powder, granule, microcapsule, etc. Liquid mode, or semi-liquid, cream, paste, gel
  • the form of the pill which enclosed the aspects, such as a shape, in the capsule and the seamless capsule is illustrated.
  • the dosage form of the composition for internal use of the present invention is preferably a tablet, more preferably an enteric solvent. Whether it is an enteric solvent can be confirmed by the 14th revised Japanese Pharmacopoeia disintegration test method.
  • the method for producing the composition for internal use of the present invention is not particularly limited, and can be appropriately selected according to the dosage form.
  • a manufacturing method when the dosage form is a tablet lactoferrin, fucoxanthin, and any components that can be blended as necessary are mixed, and the resulting mixture is compression-molded to obtain a tablet.
  • a method of coating the obtained tablet with an enteric component (method of making enteric solvent) is exemplified, and the latter method is preferred.
  • Enteric components include alginate, shellac, hydroxymethylcellulose phthalate, carboxymethylcellulose, cellulose acetate phthalate, ethylcellulose, methacrylic acid copolymers such as aminoalkyl methacrylate copolymer, brewer's yeast cell wall (example: yeast wrap), tapioca starch And gelatin, pectin and the like.
  • the internal use composition of the present invention may itself be directly administered to the application target, or may be added to a food or a food composition (eg, functional food), a medicine or a pharmaceutical composition and administered. Good.
  • the composition for internal use of the present invention can be a food additive composition.
  • the food additive composition of the present invention may further contain an optional component contained in the food additive composition.
  • the food additive composition of the present invention may or may not be designated as a food additive by a public organization.
  • the medicine may be a so-called medicine or a quasi drug.
  • the food is not particularly limited, and may be any of health foods, functional foods, health functional foods, foods for specified health use, functional nutritional foods and nutritional supplements, and foods for which the target person is limited (eg: Infant food, elderly food, patient food).
  • composition for internal use of the present invention When applying the composition for internal use of the present invention, other body fat reducing agents, neutral fat reducing agents, dyslipidemic agents and the like may be applied together.
  • the application of the composition for internal use of the present invention may be combined with the application of a therapy such as diet therapy or exercise therapy.
  • Components (a) and (b) are useful as active ingredients for body fat reducing agents.
  • the body fat reducing agent of the present invention may contain any component other than the components (a) and (b), and the optional components are the same as those described for the composition for internal use. Definition of body fat reduction, purpose of ingestion of body fat reducing agent, application target and its health condition, administration method, optional ingredients, production method, food and pharmaceutical use are the same as the respective explanations for the composition for internal use It is.
  • Components (a) and (b) are useful as active ingredients for neutral fat reducing agents.
  • the neutral fat reducing agent of the present invention may contain optional components other than the components (a) and (b), and the optional components are the same as those described for the composition for internal use. Definition of neutral fat reduction, purpose of intake of neutral fat reducing agent, application target and its health condition, administration method, optional ingredients, manufacturing method, food and pharmaceutical use, each description of the composition for internal use It is the same.
  • Components (a) and (b) are also useful as active ingredients for weight loss promoters, obesity prevention or inhibitors. These agents may contain arbitrary components other than components (a) and (b), and the optional components are the same as those described for the composition for internal use.
  • the application target and its health condition, administration method, optional ingredients, production method, food and pharmaceutical use are the same as those described for the composition for internal use.
  • the administration form of the agent of the present invention is not particularly limited, and for example, oral administration (for example, buccal administration, sublingual administration, etc.), parenteral administration (intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, Nasal administration, pulmonary administration, etc.).
  • oral administration for example, buccal administration, sublingual administration, etc.
  • parenteral administration intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, Nasal administration, pulmonary administration, etc.
  • a less invasive dosage form is preferable, oral administration is more preferable, and oral administration as a food is further preferable.
  • purification process is 1% fucoxanthin oil, crude fucoxanthin, and refined fucoxanthin, respectively.
  • Example 1 and Example 2 KK-Ay mice (male, 5 weeks old), an obese model animal, were evaluated for body weight, body fat reduction, and reduction of triglycerides and free fatty acids.
  • X-RAY CT SYSTEM SMX-100CT: manufactured by Shimadzu Corporation
  • Lipid concentration in plasma was determined using triglyceride E-Test Wako (Wako Pure Chemical Industries, Ltd.) and NEFA-C Test Wako (Wako Pure Chemical Industries, Ltd.). did. The average values of visceral fat area, subcutaneous fat mass and body weight were calculated.
  • Table 1 shows reduction rates of visceral fat area, subcutaneous fat mass and body weight in each example.
  • Table 2 shows the respective reduction rates of triglyceride and free fatty acid in each Example.
  • the LF 1% + FX 0.1% group (Example 1)
  • the body weight, visceral fat area and subcutaneous fat mass showed a large decrease rate (Table 1).
  • the body weight, the visceral fat area, and the reduction rate of Comparative Example 1, Comparative Example 2, and the FX0.001% group (Comparative Example 4) A large decrease in the amount of subcutaneous fat was shown.
  • the weight loss rate in the LF1% + FX0.1% group is the weight loss rate in the LF1% group (Comparative Example 1) and the weight loss rate in the FX0.1% group (Comparative Example 3).
  • the synergistic effect of the combination of lactoferrin and fucoxanthin was confirmed, which was significantly larger than the added value.
  • the rate of weight loss in the LF 1% + FX 0.1% group is larger than that in the LF 5% group (Comparative Example 2) in which the amount of lactoferrin added is five times, and lactoferrin and fucoxanthin In combination, it was confirmed that there was a weight loss effect exceeding that when a large amount of lactoferrin was added. The same was true for visceral fat area, subcutaneous fat mass, triglyceride and free fatty acid concentrations.
  • the rate of decrease in body weight in the LF1% + FX0.001% group is the rate of decrease in body weight in the LF1% group (Comparative Example 1) and the rate of decrease in body weight in the FX0.001% group (Comparative Example 4).
  • the synergistic effect of the combination of lactoferrin and fucoxanthin was confirmed, which was significantly larger than the added value.
  • the rate of weight loss in the LF1% + FX0.001% group is larger than that in the LF5% group (Comparative Example 2) in which the amount of lactoferrin added is five times, and lactoferrin and fucoxanthin In combination, it was confirmed that there was a weight loss effect exceeding that when a large amount of lactoferrin was added. The same was true for visceral fat area, subcutaneous fat mass, triglyceride and free fatty acid concentrations.
  • composition for internal use of the present invention has an effect of reducing body weight, body fat, blood triglyceride and / or blood free fatty acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2015/085450 2014-12-19 2015-12-18 内服用組成物 WO2016098874A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020177015167A KR20170095843A (ko) 2014-12-19 2015-12-18 내복용 조성물
CN201580069149.8A CN107106633A (zh) 2014-12-19 2015-12-18 内服用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014257747A JP6399920B2 (ja) 2014-12-19 2014-12-19 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤
JP2014-257747 2014-12-19

Publications (1)

Publication Number Publication Date
WO2016098874A1 true WO2016098874A1 (ja) 2016-06-23

Family

ID=56126754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/085450 WO2016098874A1 (ja) 2014-12-19 2015-12-18 内服用組成物

Country Status (5)

Country Link
JP (1) JP6399920B2 (enrdf_load_stackoverflow)
KR (1) KR20170095843A (enrdf_load_stackoverflow)
CN (1) CN107106633A (enrdf_load_stackoverflow)
TW (1) TWI691334B (enrdf_load_stackoverflow)
WO (1) WO2016098874A1 (enrdf_load_stackoverflow)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006083102A (ja) * 2004-09-16 2006-03-30 Four Leaf Japan:Kk 抗酸化組成物およびこれを含む製品
WO2006126325A1 (ja) * 2005-05-24 2006-11-30 National University Corporation Hokkaido University 抗肥満活性剤及び肥満抑制方法
JP2008069121A (ja) * 2006-09-15 2008-03-27 Lion Corp 脂肪減少促進剤
JP2011001333A (ja) * 2009-06-22 2011-01-06 Lion Corp アシル−ＣｏＡ合成阻害剤
JP2013060402A (ja) * 2011-09-14 2013-04-04 Furabamin:Kk フコキサンチンおよびフコイダン含有組成物
WO2014028585A1 (en) * 2012-08-14 2014-02-20 The Texas A&M University System Compositions for targeted anti-aging therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101721403A (zh) * 2008-10-16 2010-06-09 北京绿色金可生物技术股份有限公司 岩藻黄素在减肥方面的应用
WO2012099238A1 (ja) * 2011-01-21 2012-07-26 ライオン株式会社 脂肪分解促進組成物
CN103012327B (zh) * 2012-12-21 2015-05-13 国家海洋局第三海洋研究所 岩藻黄质的制备方法
JP6208604B2 (ja) * 2014-03-14 2017-10-04 ライオン株式会社 体脂肪低減剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006083102A (ja) * 2004-09-16 2006-03-30 Four Leaf Japan:Kk 抗酸化組成物およびこれを含む製品
WO2006126325A1 (ja) * 2005-05-24 2006-11-30 National University Corporation Hokkaido University 抗肥満活性剤及び肥満抑制方法
JP2008069121A (ja) * 2006-09-15 2008-03-27 Lion Corp 脂肪減少促進剤
JP2011001333A (ja) * 2009-06-22 2011-01-06 Lion Corp アシル−ＣｏＡ合成阻害剤
JP2013060402A (ja) * 2011-09-14 2013-04-04 Furabamin:Kk フコキサンチンおよびフコイダン含有組成物
WO2014028585A1 (en) * 2012-08-14 2014-02-20 The Texas A&M University System Compositions for targeted anti-aging therapy

Also Published As

Publication number Publication date
CN107106633A (zh) 2017-08-29
KR20170095843A (ko) 2017-08-23
TWI691334B (zh) 2020-04-21
JP6399920B2 (ja) 2018-10-03
JP2016117676A (ja) 2016-06-30
TW201625293A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
JP6016363B2 (ja) 脳神経細胞新生剤
JP2005068060A (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
WO2007029631A1 (ja) 体内脂質改善組成物
KR20080108523A (ko) 지방 축적 억제제
JP6293099B2 (ja) ジンセノサイドｆ２の肝疾患予防又は治療用途
TWI610680B (zh) 含有去鼠李糖洋丁香酚苷（Ｄｅｓ Ｒｈａｍｎｏｓｙｌ Ａｃｔｅｏｓｉｄｅ）之橄欖萃取物
JP5158307B2 (ja) 脂肪減少促進剤及び代謝異常症候群改善薬
KR100828069B1 (ko) 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물
JP2013071909A (ja) 脳内過酸化脂質蓄積抑制剤
EP2908828B1 (en) Galactagogue compositions based on phosphatidylserine
JP6460402B2 (ja) コレステロール排出促進用医薬組成物又は食品組成物
CN108420890B (zh) 一种具有降血脂作用的组合物及其制备方法
JP5955236B2 (ja) 血中クレゾール低下剤
JP6399920B2 (ja) 体脂肪低減剤、体重減少促進剤、血中中性脂肪低減剤及び血中遊離脂肪酸低減剤
JP2011246434A (ja) フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、ｔｇ低下剤、糞中脂肪排泄促進剤
JP5546833B2 (ja) アセトアルデヒド・エタノール低減剤
JP2022118264A (ja) 脂質排泄促進剤
JP7088777B2 (ja) Ｇｌｕｔ１発現亢進剤
WO2021152400A1 (en) Compositions comprising pig stomach mucins and uses thereof
WO2022085603A1 (ja) 筋量増加、筋力増加、筋量減少抑制又は筋力低下抑制用組成物
JP2004002254A (ja) 植物抽出エキスを含有する腸溶性の脂肪吸収抑制剤およびそれを含有する食品
JP2018008912A (ja) 臓器線維化抑制組成物
JP2016060736A (ja) 糖代謝改善剤
JP2024051747A (ja) 炎症性腸疾患改善剤、炎症性腸疾患改善用食品添加剤、炎症性腸疾患改善用飲食品、炎症性腸疾患改善用製剤
TW202513087A (zh) 腎功能之增進或改善用組合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15870073

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20177015167

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15870073

Country of ref document: EP

Kind code of ref document: A1